Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CancerAneuploidy

Financiado

Cerrado

Understanding and targeting the functional consequences of aneuploidy in cancer

Aneuploidy, an imbalanced number of chromosomes or chromosome arms, is a distinct feature of cancer. Recent years have seen conceptual, methodological and technical advances in the field of cancer aneuploidy research, but we are j... ver más

30/09/2026

TAU

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-12-02

ERC-2020-STG: ERC STARTING GRANTS

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

TAU

1.61M€ | Lider

CEMENTOS MOLINS INDUSTRIAL

1.69M€ | Participante

Proyectos interesantes

IJCI-2016-29550

Medical Technol...

Data Science

64K€ Cerrado

MultiCloneSeq

Medical Technol...

Data Science

150K€ Cerrado

EVOEPIC

Medical Technol...

Data Science

1M€ Cerrado

OncIndLymph

Medical Technol...

Data Science

100K€ Cerrado

SHATTER-AML

Medical Technol...

Data Science

2M€ Cerrado

BIO2014-52566-R

Medical Technol...

Data Science

182K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 69 meses Fecha Inicio: 2020-12-02
Fecha Fin: 2026-09-30

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Aneuploidy, an imbalanced number of chromosomes or chromosome arms, is a distinct feature of cancer. Recent years have seen conceptual, methodological and technical advances in the field of cancer aneuploidy research, but we are just beginning to scratch the surface of the underlying biology, and the potential vulnerabilities of aneuploid cancer cells remain under-explored. Cancer aneuploidy is therefore a biological enigma and a missed opportunity for cancer therapy. Identifying the Achilles heels of aneuploidy remains a holy grail of cancer research. However, current models of aneuploidy fail to fully recapitulate the cellular consequences of aneuploidy in cancer, thus compromising the identification of aneuploidy-induced cellular vulnerabilities. The time is ripe to tackle cancer aneuploidy with state-of-the-art genomic and functional approaches. In this project, I propose to address the following key questions: 1) What forces shape the evolution of aneuploidy in tumors? We will integrate in silico analyses of clinical data, in vitro modeling in isogenic human cell lines, and in vivo experiments in mice, to elucidate how various cellular contexts shape the tumor aneuploidy landscape. 2) What cellular vulnerabilities are induced by aneuploidy? We will combine isogenic cell lines with large-scale genetic and chemical perturbation screens, in order to identify, validate, and mechanistically dissect vulnerabilities induced by aneuploidy in human cancer cells. These research aims fall well within my unique expertise. I mapped various aneuploidy landscapes and developed innovative experimental and computational tools for studying cancer aneuploidy. A successful completion of the project will shed light on the context-dependent cellular consequences of aneuploidy in cancer and provide proof-of-concept for its potential targeting. Ultimately, identifying aneuploidy-specific vulnerabilities will pave the way for the therapeutic exploitation of this hallmark of cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores